Neurological manifestations in critically ill patients;Manifestaciones neurológicas del paciente en estado crítico

Revista de Neurologia

Volumn 43, Issue 3, 2006, Pages 155-167

  Lopez Rodriguez L ^a   Hidalgo Alquicira, F G ^a   Mimenza Alvarado, Alberto José ^a  

^a HOSPITAL REGIONAL LIC ADOLFO LÓPEZ MATEOS   (Mexico)

Author keywords

Critical; Encephalopathy; Myopathy; Pathophysiology; Polyneuropathy; Sepsis

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ASCORBIC ACID; BETAMETHASONE; CYCLOSPORIN; DEXAMETHASONE; FLUORINATED STEROID; LABETALOL; MAGNESIUM SULFATE; METRONIDAZOLE; NEUROMUSCULAR BLOCKING AGENT; NEUROTRANSMITTER; OMEPRAZOLE; PHENYTOIN; PROPOFOL; TACROLIMUS; ADRENERGIC RECEPTOR BLOCKING AGENT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; ANTIULCER AGENT; IMMUNOSUPPRESSIVE AGENT; INTRAVENOUS ANESTHETIC AGENT;

ARTIFICIAL VENTILATION; ATAXIA; BRAIN DISEASE; CARDIOMYOPATHY; CLINICAL FEATURE; COMA; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; CRITICAL ILLNESS; DISEASE CLASSIFICATION; DRUG ERUPTION; DYSARTHRIA; DYSPNEA; ELECTROMYOGRAPHY; EXCITOTOXICITY; FEVER; HEART INFARCTION; HICCUP; HOSPITAL DISCHARGE; HUMAN; HYPERREFLEXIA; HYPERTROPHIC CARDIOMYOPATHY; HYPOXIA; INTENSIVE CARE; LYMPHADENOPATHY; METABOLIC ACIDOSIS; MUSCLE WEAKNESS; MYALGIA; MYOPATHY; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; NEUROPATHY; NEUROTOXICITY; NYSTAGMUS; PATHOPHYSIOLOGY; POLYNEUROPATHY; PROGNOSIS; REVIEW; RHABDOMYOLYSIS; SEPSIS; SIDE EFFECT; DIFFERENTIAL DIAGNOSIS; INTENSIVE CARE UNIT; METABOLISM; PATHOLOGY;

ADRENERGIC ANTAGONISTS; AMINOGLYCOSIDES; AMIODARONE; ANESTHETICS, INTRAVENOUS; ANTI-ARRHYTHMIA AGENTS; ANTI-INFECTIVE AGENTS; ANTI-ULCER AGENTS; ANTICONVULSANTS; CRITICAL ILLNESS; CYCLOSPORINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTENSIVE CARE UNITS; LABETALOL; METRONIDAZOLE; NEUROMUSCULAR DISEASES; OMEPRAZOLE; PHENYTOIN; POLYNEUROPATHIES; PROGNOSIS; PROPOFOL; SEPSIS; TACROLIMUS;

EID: 35348926973     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.4303.2005775     Document Type: Review

References (50)

1. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 2003; 29: 530-8.
2. Calandra T, Cohen J. The Internacional Sepsis Forum Consensus Conference on Definitions of Infection in the Intensive Care Unit. Crit Care Med 2005; 33: 1538-48.
3. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign quidelines for management of severe sepsis and septic shock. Intensive Care Med 2004; 30: 536-55.
4. Wilson JX, Young GB. Sepsis-associated encephalopathy: evolving concepts. Can J Neurol Sci 2003; 30: 98-105.
5. Gonsales G, De Gaudio AR. Sepsis associated encephalopathy. Minerva Anestesiol 2005; 71: 39-52.
6. Barlas I, Oropello JM, Benjamín E. Neurologic complications in intensive care. Curr Opin Crit Care 2001, 7: 68-73.
7. Davies DC. Blood-brain barrier breakdown in septic encephalopathy and brain tumours. J Anat 2002; 200: 639-46.
8. Stephan F, Novara A, Tournier B, Maillet JM, London GM, Safar ME, et al. Determination of total effective vascular compliance in patients with sepsis syndrome. Am J Respir Crit Care Med 1998; 157: 50-6.
9. Hawkins BT, Davis TP. The blod-brain barier/neurovascular unit in health and disease. Pharmacol Rev 2005; 57: 173-85.
10. Terborg C, Schummer W, Albrecht M, Reinhart K, Weiller C, Röther J. Dysfunction of vasomotor reactivity in severe sepsis and septic shock. Intensive Care Med 2001; 27: 1231-4.
11. Sharshar T, Annane D, Lorin de la Grandmaison G, Brouland JP, Hopkinson NS, Gray F. The neuropathology of septic shock. Brain Pathol 2004; 14: 21-33.
12. De Backer D, Creteur J, Preiser JC, Dubois MJ, Vincent JL. Microvascular blood flow is altered in patients with sepsis. Am J Respir Crit Care Med 2002; 166: 98-104.
13. Basler T, Meier-Hellmann A, Bredle D, Reinhart K. Amino acid imbalance early in septic encephalopathy. Intensive Care Med 2002; 28: 293-8.
14. Milbrandt EB, Angus DC. Potential mechanisms and markers of critical illness-associated cognitive dysfunction. Curr Opin Crit Care 2005; 11: 355-9.
15. Eidelman LA, Putterman D, Putterman C, Sprung CL. The spectrum of septic encephalopathy: definitions, etiologies, and mortalities. JAMA 1996; 275: 470-3.
16. Zauner C, Gendo A, Kramer L, Funk GC, Bauer E, Schenk P, et al. Impaired subcortical and cortical sensory evoked potential pathways in septic patients. Crit Care Med 2002; 30: 1136-9.
17. Esen F, Erdem T, Aktan D, Orhan M, Kaya M, Eraksoy H, et al. Effect of magnesium sulfate administration on blood-brain barrier in a rat model of intraperitoneal sepsis: a randomized controlled experimental study. Crit Care 2005; 9: R18-23.
18. Mayer K, Gokorsch S, Fegbeutel C, Hattar K, Rosseau S, Walmrath D, et al. Parenteral nutrition with fish oil modulates cytokine response in patients with sepsis. Am J Respir Crit Care Med 2003; 167: 1321-8.
19. Hopkins RO, Brett S. Chronic neurocognitive effects of critical illness. Curr Opin Crit Care 2005; 11: 369-75.
20. Van Mook W, Hulsewé-Evers R. Critical illness polyneuropathy. Curr Opin Crit Care 2002, 8: 302-10.
21. Gurtubay IG, Morales G, Navajas D, Carrera B, Iragui M. Alteraciones neuromusculares del paciente crítico. Rev Neurol 1998; 26: 53-7.
22. Bolton CF. Neuromuscular manifestations of critical illness. Muscle Nerve 2005; 32: 140-63.
23. Miranda M, Arroyo HA, Ledesma D, Sasbon J, Medina C, Fejerman N. Polineuropatía del paciente crítico pediátrico: una causa poco reconocida de dependencia al respirador. Rev Neurol 2001; 32: 838-43.
24. Hund E. Critical illness polyneuropathy. Curr Opin Neurol 2001, 14: 649-53.
25. De Letter MA, Schmitz PI, Visser LH, Verheul FA, Schellens RL, Op de Coul DA, et al. Risk factors for the development of polineuropathy and myopathy in critically ill patients. Crit Care Med 2001; 29: 2281-6.
26. Leijten FS, De Weerd AW, Poortvliet DC, De Ridder VA, Ulrich C, Harinck-De Weerd JE. Critical illness polineuropathy in multiple organ dysfunction syndrome and weaning from the ventilator. Intensive Care Med 1996; 22: 856-61.
27. Leijten FS, Harinck-De Weerd JE, Poortvliet DC, De Weerd AW. The role of polineuropathy in motor convalescence after prolonged mechanical ventilation. JAMA 1995; 274: 1221-5.
28. Van den Berghe G, Whouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med 2001, 345: 1359-67.
29. Lorin S, Nierman DM. Critical illness neuromuscular abnormalities. Crit Care Clin 2002; 18: 553-68.
30. Latronico N, Peli E, Botteri M. Critical illness myopathy and neuropathy. Curr Opin Crit Care 2005, 11: 126-32.
31. Garnacho-Montero J, Madrazo-Osuna J, García-Garmendia JL, Ortiz-Leyba C. Neuromuscular disorders of the critically ill patient. Clinical Pulmonary Medicine 2001; 8: 354-9.
32. De Jonghe B, Sharshar T, Lefaucheur JP, Outin H. Critical illness neuromyopathy. Clinical Pulmonary Medicine 2005; 12: 90-6.
33. Mohr M, Englisch L, Roth A, Burchardi H, Zielmann S. Effects of early treatment with immunoglobulin on critical illness polyneuropathy following multiple organ failure and gram-negative sepsis. Intensive Care Med 1997, 23: 1144-9.
34. Murray MJ, Cowen J, DeBlock H, Erstad B, Gray AW, Tescher AN, et al. Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient. Crit Care Med 2002; 30: 142-56.
35. Vender JS, Szokol JW, Murphy GS, Nitsun M. Sedation, analgesia, and neuromuscular blockade in sepsis: an evidence-based review. Crit Care Med 2004; 32 (Suppl 11); S554-61.
36. Fletcher SN, Kennedy DD, Ghosh IR, Misra VP, Kiff K, Coakley JH, et al. Persistent neuromuscular and neurophysiologic abnormalities in long-term survivors of prolonged critical illness. Crit Care Med 2003; 31: 1012-6.
37. Hund, E. Myopathy in critically ill patients. Crit Care Med 1999, 27: 2544-7.
38. Naguib M, Flood P, McArdle JJ, Brenner HR. Advances in neurobiology of the neuromuscular junction. Implications for the anesthesiologist. Anesthesiology 2002; 96: 202-31.
39. Gutmann L, Gutmann L. Critical Illness neuropathy and myopathy. Arch Neurol 1999; 56: 527-8.
40. Lanone S, Mebazaa A, Heymes C, Henin D, Poderoso JJ, Panis Y, et al. Muscular contractile failure in septic patients. Role of the inducible niric oxide synthase pathway. Am J Respir Crit Care Med 2000; 162: 2308-15.
41. Brealey D, Brand M, Hargreaves I, Heales S, Land J, Smolenski R, et al. Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 2002; 360: 219-23.
42. Di Giovanni S, Molon A, Broccolini A, Melcon G, Mirabella M, Hoffman E, et al. Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol 2004; 55: 195-206.
43. Walsh RJ, Amato AA. Toxic myopathies. Neurol Clin 2005; 23: 397-428.
44. Showalter CJ, Engel AG. Acute quadriplegic myopathy: analysis of myosin isoforms and evidence for calpain-mediated proteolysis. Muscle Nerve 1997; 20: 316-22.
45. Zatz M, Starling A. Calpains and disease. N Engl J Med 2005; 352: 2413-23.
46. Larsson L, Li X, Edstrom L, Eriksson LI, Zackrisson H, Argentini C, et al. Acute quadriplegia and loss of muscle myosin in patients treated with nondepolarizing neuromuscular blocking agents and corticos teroids: mechanisms at the cellular and molecular levels. Crit Care Med 2000; 28: 34-45.
47. Lacomis D, Zochodne DW, Bird SJ. Critical illness myopathy. Muscle Nerve 2000; 23: 1785-8.
48. Saleh FG, Seidman RJ. Drug-induced myopathy and neuropathy. Journal of Clinical Neuromuscular Disease 2003; 5: 81-92.
49. De Schoenmakere G, De Waele J, Terryn W, Deweweire M, Verstraete A, Hoste E, et al. Phenytoin intoxication in critically ill patients. Am J Kidney Dis 2005; 45: 189-92.
50. Pasquale TR, Tan JS. Nonantimicrobial effects of antibacterial agents. Clin Infect Dis 2005; 40: 127-35.